TScan Therapeutics, Inc. $TCRX Shares Sold by EcoR1 Capital LLC

Key Points

• EcoR1 Capital LLC reduced its holdings in TScan Therapeutics by 86.7%, selling 4,337,167 shares and now owns approximately 1.17% of the company.
• Despite this significant sell-off, TScan Therapeutics has a consensus rating of "Buy" from analysts, with an average price target of $7.80.
• TScan Therapeutics reported a quarter earnings of ($0.28) per share, meeting consensus estimates, and generated $3.08 million in revenue, surpassing expectations.

EcoR1 Capital LLC reduced its holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 86.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 662,833 shares of the company's stock after selling 4,337,167 shares during the period. EcoR1 Capital LLC owned approximately 1.17% of TScan Therapeutics worth $915,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in TCRX. Wells Fargo & Company MN lifted its position in TScan Therapeutics by 41.1% during the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after buying an additional 5,694 shares in the last quarter. Barclays PLC lifted its position in TScan Therapeutics by 16.3% during the fourth quarter. Barclays PLC now owns 67,508 shares of the company's stock worth $206,000 after buying an additional 9,441 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in TScan Therapeutics by 108.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company's stock worth $851,000 after buying an additional 145,731 shares in the last quarter. Stifel Financial Corp lifted its position in TScan Therapeutics by 10.7% during the fourth quarter. Stifel Financial Corp now owns 109,700 shares of the company's stock worth $333,000 after buying an additional 10,567 shares in the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in TScan Therapeutics during the fourth quarter worth approximately $198,000. Hedge funds and other institutional investors own 82.83% of the company's stock.

TScan Therapeutics Trading Up 1.1%

Shares of NASDAQ TCRX traded up $0.02 during midday trading on Friday, reaching $1.91. 270,203 shares of the stock were exchanged, compared to its average volume of 195,354. The company has a 50 day simple moving average of $1.76 and a 200 day simple moving average of $1.62. The stock has a market capitalization of $108.39 million, a P/E ratio of -1.75 and a beta of 1.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.06 and a current ratio of 7.06. TScan Therapeutics, Inc. has a twelve month low of $1.02 and a twelve month high of $6.23.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.28). The business had revenue of $3.08 million during the quarter, compared to the consensus estimate of $1.31 million. TScan Therapeutics had a negative net margin of 1,964.88% and a negative return on equity of 63.33%. As a group, equities analysts expect that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on TCRX. Wedbush restated an "outperform" rating and set a $7.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, August 12th. Wall Street Zen upgraded shares of TScan Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $7.80.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.